A startup spawned from Oxford University is trying to commercialize components of a quantum computing technology that could ultimately improve the downstream end of existing diagnostic devices.
News & Features
RenalytixAI has raised $29 million to help advance tests for early detection of kidney disease and a test that will help in the accurate management of kidney transplant rejection.
The Marlborough, MA-based company hasn’t been shy about building up its portfolio through M&A, the only question now is can it slip in another deal before the end of the year.
Anti-counterfeiting poses a challenge for medical equipment OEMs. However, newer technology ushers in a problem solver hard to beat.
The Mountain View, CA-based company isn’t out of diabetes completely, as it still has partnerships in the space with DexCom, Sensile, and Sanofi.
Users can get a trial run of the neuromodulation therapy before having the Proclaim DRG system implanted.
Artificial intelligence–powered software prioritizes the assessment of computed tomography cases that may have indications of brain bleed.
One year into the transition periods for the new EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), industry experts continue to express concern that more progress is needed to help companies prepare for the new regulations within the limited transition period.
News of Edwards Lifesciences' CE mark for Sapien 3 Ultra was dampened by Boston Scientific's preliminary injunction on the device in Germany.
The Galway, Ireland-based company is now aimed at gaining FDA approval, but Teleflex is looking to enter the U.S. market and Abbott Laboratories has leading share in the space.
The Irvine, CA-based company estimates it could get a PMA for its rechargeable sacral neuromodulation to treat urinary dysfunction and fecal dysfunction sometime in 2019.